Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: The Post-Truth Biopharma Rally

Executive Summary

The post-election rally in biopharmaceutical stocks was driven partly by hopes that drug pricing pressures will evaporate. However, this is a facet of post-truth culture rather than a real possibility. As Teva, Mylan and maybe Novartis have demonstrated, more is less when it comes to generic exposure.

You may also be interested in...



Bevacizumab Biosimilar Nears Market As Amgen Files First At FDA

What is believed to be the first biosimilar version of Roche's Avastin to be filed with the US FDA has come from Amgen working in collaboration with Allergan, with the two companies heading a dozen-strong group of companies racing to develop versions of the monoclonal antibody.

Teva Hits Pause On Business Development, Even As Some Deals Stumble

Teva CEO Erez Vigodman said the company will step away from business development for the “foreseeable future” while it digests the acquisition of Allergan’s generic drug business.

Mylan Finally Nabs Meda In Diversification Play

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel